Yesterday TreatSMA along with three other charities signed an open letter to the managers at Biogen. The letter, which you can read below, is a direct fallout of the recent SMC decision on restricting Spinraza to patients with SMA type 1 only in which the Consortium hinted to the Spinraza pricing as the key factor.